Get the Stockscreener App
26.14
1.91%
-0.56
Centessa Pharmaceuticals Plc Adr stock is traded at $26.14, with a volume of 51,461.
It is down -1.91% in the last 24 hours and up +11.26% over the past month.
Centessa Pharmaceuticals PLC is a clinical-stage pharmaceutical company. The company's pipeline assets include: SerpinPC for Hemophilia A, B; LB101 for Solid Tumors; ORX750 for Narcolepsy Type 1 (NT1) and other sleep disorders; MGX292 Pulmonary Arterial Hypertension (PAH); and Undisclosed for Solid Tumors.
See More
Previous Close:
$26.70
Open:
$26.71
24h Volume:
51,461
Relative Volume:
0.04
Market Cap:
$3.86B
Revenue:
$15.06M
Net Income/Loss:
$-242.05M
P/E Ratio:
-14.36
EPS:
-1.8204
Net Cash Flow:
$-181.28M
1W Performance:
-2.17%
1M Performance:
+11.26%
6M Performance:
+66.50%
1Y Performance:
+54.42%
1-Day Range:
$25.95
$27.02
1-Week Range:
$25.38
$27.37
52-Week Range:
$9.60
$30.58
Centessa Pharmaceuticals Plc Adr Stock (CNTA) Company Profile
Name
Centessa Pharmaceuticals Plc Adr
Sector
Industry
Phone
44 7391 789784
Address
3RD FLOOR, ALTRINCHAM, CHESHIRE
Compare CNTA vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CNTA
Centessa Pharmaceuticals Plc Adr
|
26.08 | 3.95B | 15.06M | -242.05M | -181.28M | -1.8204 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.94 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
774.57 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
730.65 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
322.71 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
295.05 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Centessa Pharmaceuticals Plc Adr Stock (CNTA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-10-25 | Resumed | Oppenheimer | Outperform |
| Oct-28-25 | Initiated | Stephens | Overweight |
| Sep-03-25 | Initiated | Wells Fargo | Overweight |
| Aug-29-25 | Resumed | Oppenheimer | Outperform |
| Jul-21-25 | Initiated | Truist | Buy |
| May-28-25 | Initiated | Needham | Buy |
| May-08-25 | Initiated | Chardan Capital Markets | Buy |
| Mar-31-25 | Initiated | Piper Sandler | Overweight |
| Jan-07-25 | Initiated | TD Cowen | Buy |
| Sep-20-24 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Sep-19-24 | Initiated | B. Riley Securities | Buy |
| Jul-18-24 | Initiated | Oppenheimer | Outperform |
| Nov-15-23 | Upgrade | Jefferies | Hold → Buy |
| Oct-26-23 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Jun-21-23 | Initiated | Evercore ISI | Outperform |
| Jun-12-23 | Initiated | Guggenheim | Buy |
| Mar-17-23 | Initiated | SVB Securities | Outperform |
| Aug-12-22 | Downgrade | Morgan Stanley | Overweight → Underweight |
| Jun-17-22 | Initiated | BMO Capital Markets | Outperform |
| Jun-03-22 | Downgrade | Jefferies | Buy → Hold |
| Feb-11-22 | Initiated | Goldman | Neutral |
View All
Centessa Pharmaceuticals Plc Adr Stock (CNTA) Latest News
Royce & Associates LP Acquires New Holdings in Centessa Pharmaceuticals PLC Sponsored ADR $CNTA - MarketBeat
CNTA Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
TD Asset Management Inc Trims Position in Centessa Pharmaceuticals PLC Sponsored ADR $CNTA - MarketBeat
Forget Centessa Pharmaceuticals: This Rare‑Disease Specialist Has a Superior Portfolio and Pipeline - The Motley Fool
Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) Given Consensus Recommendation of “Buy” by Brokerages - Defense World
Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) Given Consensus Recommendation of "Buy" by Brokerages - MarketBeat
Centessa Pharmaceuticals PLC Sponsored ADR $CNTA Shares Sold by Aberdeen Group plc - Defense World
Eagle Health Investments LP Makes New Investment in Centessa Pharmaceuticals PLC Sponsored ADR $CNTA - MarketBeat
Orexin-2 Receptor Data Reinforces a Positive Outlook for Centessa (CNTA) - Finviz
Centessa Pharmaceuticals CEO Teases “Transformational” 2026 as ORX750 Nears Registrational Trials - Yahoo Finance
Centessa (CNTA) sets Dr. Saurabh Saha advisory role and exit package - Stock Titan
Centessa Pharmaceuticals (NASDAQ:CNTA) Shares Gap DownWhat's Next? - MarketBeat
Insider Selling: Centessa Pharmaceuticals (NASDAQ:CNTA) Insider Sells 1,010 Shares of Stock - MarketBeat
Iqbal Hussain Sells 38,951 Shares of Centessa Pharmaceuticals (NASDAQ:CNTA) Stock - MarketBeat
Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) Receives Consensus Rating of “Moderate Buy” from Analysts - Defense World
Federated Hermes Inc. Purchases Shares of 1,749,650 Centessa Pharmaceuticals PLC Sponsored ADR $CNTA - MarketBeat
Centessa Pharmaceuticals (NASDAQ:CNTA) Sees Strong Trading VolumeTime to Buy? - MarketBeat
Centessa Pharmaceuticals (CNTA) Upgraded to Buy: What Does It Mean for the Stock? - MSN
Truist Hikes Centessa (CNTA) PT to $33 While Maintaining Consistent 2026 Thesis - Finviz
A Look At Centessa Pharmaceuticals (CNTA) Valuation After New Analyst Focus On Orexin Pipeline Expansion - Sahm
Needham Hikes Centessa (CNTA) PT to $38 on High Potential for ORX-750 Trial Success and M&A Appeal - Finviz
Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) Given Average Rating of “Moderate Buy” by Brokerages - Defense World
Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) Receives Consensus Recommendation of "Buy" from Analysts - MarketBeat
Armistice Capital LLC Lowers Position in Centessa Pharmaceuticals PLC Sponsored ADR $CNTA - Defense World
oracle, visa among market cap stock movers on thursday By Investing.com - Investing.com UK
oracle, visa among market cap stock movers on thursday - Investing.com India
Russell Investments Group Ltd. Has $1.85 Million Position in Centessa Pharmaceuticals PLC Sponsored ADR $CNTA - MarketBeat
Centessa appoints orexin program founder Accardi as new CEO - Investing.com
Top investors say Centessa Pharmaceuticals plc ADR (CNTA) ticks everything they need - setenews.com
Stempoint Capital LP Increases Stock Holdings in Centessa Pharmaceuticals PLC Sponsored ADR $CNTA - MarketBeat
Accardi sells Centessa (CNTA) shares worth $288,288 - Investing.com
Centessa Pharma president sells shares for $300,000 By Investing.com - Investing.com South Africa
Analysts Boost Centessa Pharmaceuticals plc (CNTA) Price Targets as Sleep Disorder Drug Shows Breakthrough Results - Finviz
Insider Selling: Centessa Pharmaceuticals (NASDAQ:CNTA) Insider Sells 10,000 Shares of Stock - MarketBeat
Centessa Pharma president sells shares for $300,000 - Investing.com India
100,362 Shares in Centessa Pharmaceuticals PLC Sponsored ADR $CNTA Purchased by Bollard Group LLC - MarketBeat
Centessa Pharmaceuticals (NASDAQ:CNTA) Hits New 1-Year HighStill a Buy? - MarketBeat
Affinity Asset Advisors LLC Sells 646,500 Shares of Centessa Pharmaceuticals PLC Sponsored ADR $CNTA - MarketBeat
Centessa Pharmaceuticals stock hits all-time high at 29.99 USD By Investing.com - Investing.com Nigeria
Centessa Pharmaceuticals stock hits all-time high at 29.99 USD - Investing.com
Saturn V Capital Management LP Acquires 344,635 Shares of Centessa Pharmaceuticals PLC Sponsored ADR $CNTA - MarketBeat
B. Riley Research Analysts Raise Earnings Estimates for CNTA - MarketBeat
OMERS ADMINISTRATION Corp Buys New Position in Centessa Pharmaceuticals PLC Sponsored ADR $CNTA - MarketBeat
American Century Companies Inc. Raises Stock Holdings in Centessa Pharmaceuticals PLC Sponsored ADR $CNTA - Defense World
Centessa Pharmaceuticals Plc Adr Stock (CNTA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.50%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):